Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-811
NCT03615326Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
A Phase 3 trial of pembrolizumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Merck & Co.. Started Oct 2018; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03615326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03615326.